Glens Falls Hospital

100 Park Street, Glens Falls, NY 12801 518.926.1000

Clinical Trials

Key:

C = CALGB
E = ECOG
N = NSABP
P = Pharmacy
R = RTOG
S = SWOG
CTSU= NCI Cancer Trials Support Unit
V = Vermont Cancer Center

 

Updated 9-5-13

 

Anemia:

P 20070782

 

  • A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin alfa Administered at 500 g Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy

Bladder:

C 90601

  • A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin and Placebo in Patients with Advanced Transitional Cell Carcinoma

Breast:

N B47

  • A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (6 Cycles of Docetaxel Plus Cyclophosphamide or 4 Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer

N B50I  

  • A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy & Safety of Trastuzumab Emtansine vs. Trastuzumab as Adjuvant Therapy for Patients with HER2-Pos. Primary Breast Cancer Who Have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Pre-Op Therapy

N B51  

  • A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (Pre-Activation Only)

PUMA NER 1301          

  • (NALA) A Study of Neratinib Plus Capecitabine vs. Lapatinib Plus Capecitabine in Patients with Her2+ Metastatic Breast Ca who Have Received >/= 2 Prior Her2-Directed Regimens in the Metastatic Setting

 

 

CTSU S1007  

  • A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with

              Recurrence Score (RS) of 25 or Less

P 20110148  

  • Randomized, single-blind study to estimate the effect of patient education on reported bone pain in breast cancer patients receiving chemotherapy and pegfilgrastim

P LEE011A2301           

  • A randomized double-blind, placebo-controlled study of LEE011 in combination with letrozole for the treatment of postmenopausal women with harmone receptor positive, HER2 negative, advanced breast cancer who received no prior therapy for advanced disease

 

 

Carcinoid:

CTSU A021202  

  • Prospective randomized phase II trial of Pazopanib vs. placebo in patients with progressive carcinoid tumors

 

Colorectal:

C 80702  

  • A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer

CTSU S0820  

  • A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)

 

Gastric/Gastroestroesophageal:

CTSU-RTOG-1010  

  • A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma

CTSU-S1201  

  • A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric, or Gastroesophageal Junction (GEJ) Cancer

Gynocological:

CTSU GOG-0273  

  • Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Head & Neck:

CTSU E-1305

  • A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab In Patients with Recurrent Or Metastatic Head and Neck Cancer

CTSU RTOG-0920  

  • A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer

Liver:

C 80802  

  • Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC).

Lung: SCLC Limited:

C 30610

  • Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide

Lung: NSCLC Advanced:

C 30610           

  • Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide

 

CTSU-E5508

  • A Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

CTSU-S0819

  • A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer

 

Lymphoma:

CTSU E1411  

  • Phase II 4-Arm Study In Patients 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV LR)

 

MDS:

CTSU E2905  

  • Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia

P Registry        

  • Celgene Corporation Connect MDS and AML: The Myelodysplastic  Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

 

Melanoma:

CTSU N0879  

  • A Randomized Phase II Trial of Carboplatin, Paclitaxel, Bevacizumab, with or without Everolimus for Therapy of Metastatic Malignant Melanoma

Pancreas:

RTOG-0848

  • A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma

CTSU S1115  

  • Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) VS mFOLFOX in Patients with Metastatic Pancreatic Cancer After Prior Chemotherapy

Prostate:

CTSU S1216  

  • A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide inPatients With Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer

 

Renal:

CTSU A031203    

  • Randomized Phase II Study Comparing Cabozantinib (NSC #761968 and IND #116059) with Commercially Supplied Sunitinib in Patients with Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma

CTSU S1107  

  • Parallel (Randomized) Phase II Evaluation of ARQ 197 and ARQ 197 in Combination with Erlotinib in Papillary Renal Cell Carcinoma - ON HOLD

 

CTSU S0931  

  • EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, a Phase III Study

 

 

Treatment Protocols

Glens Falls Hospital
Pruyn Pavilion
Research Office
Phone: (518) 926-6700
Fax: (518) 926-1954

Staff Directory

Investigators:

Robert W. Sponzo, M.D.
Aqeel Gillani, M.D.
John Stoutenburg, M.D.
Eric Pillemer, M.D.
Darci Gaiotti-Grubbs, M.D.
Mark Hoffman, M.D.

Alex Frank, M.D.

Lance Hellman, M.D.

Clinical Research Support:

Barbara Sponzo, CCRP
Beth Ann Brundage, RN, OCN
Nannette Oberhelman, CCRP
Jean VanAuken, RPA-C
Donna Boss, RPA-C